Top

BMC Psychiatry

Published in:

Open Access 01-12-2016 | Research article

Treatment adequacy of anxiety disorders among young adults in Finland

Authors: Teija Kasteenpohja, Mauri Marttunen, Terhi Aalto-Setälä, Jonna Perälä, Samuli I. Saarni, Jaana Suvisaari

Published in: BMC Psychiatry | Issue 1/2016

Abstract

Background

Anxiety disorders are common in early adulthood, but general population studies concerning the treatment adequacy of anxiety disorders taking into account appropriate pharmacological and psychological treatment are scarce. The aims of this study were to examine treatments received for anxiety disorders in a Finnish general population sample of young adults, and to define factors associated with receiving minimally adequate treatment and with dropping out from treatment.

Methods

A questionnaire containing several mental health screens was sent to a nationally representative two-stage cluster sample of 1894 Finns aged 19 to 34 years. All screen positives and a random sample of screen negatives were invited to a mental health assessment including a SCID interview. For the final diagnostic assessment, case records from mental health treatments for the same sample were obtained. This article investigates treatment received, treatment adequacy and dropouts from treatment of 79 participants with a lifetime anxiety disorder (excluding those with a single specific phobia). Based on all available information, receiving antidepressant or buspirone medication for at least 2 months with at least four visits with any type of physician or at least eight sessions of psychotherapy within 12 months or at least 4 days of hospitalization were regarded as minimally adequate treatment for anxiety disorders. Treatment dropout was rated if the patient discontinued the visits by his own decision despite having an adequate treatment strategy according to the case records.

Results

Of participants with anxiety disorders (excluding those with a single specific phobia), 41.8 % had received minimally adequate treatment. In the multivariate analysis, comorbid substance use disorder was associated with antidepressant or buspirone medication lasting at least 2 months. Those who were currently married or cohabiting had lower odds of having at least four visits with a physician a year. None of these factors were associated with the final outcome of minimally adequate treatment or treatment dropout. Participants with comorbid personality disorders received and misused benzodiazepines more often than others.

Conclusions

More efforts are needed to provide adequate treatment for young adults with anxiety disorders. Attention should be paid to benzodiazepine prescribing to individuals with personality disorders.

Available only for authorised users

Kessler RC, Angermeyer M, Anthony JC, de Graaf R, Demyttenaere K, Gasquet I, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization’s World Mental Health Survey Initiative. World Psychiatry. 2007;6(3):168–76.PubMedPubMedCentral

Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602. doi:10.1001/archpsyc.62.6.593.CrossRefPubMed

Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–79. doi:10.1016/j.euroneuro.2011.07.018.CrossRefPubMed

Saarni SI, Suvisaari J, Sintonen H, Pirkola S, Koskinen S, Aromaa A, et al. Impact of psychiatric disorders on health-related quality of life: general population survey. Br J Psychiatry. 2007;190(4):326–32. doi:10.1192/bjp.bp.106.025106.CrossRefPubMed

Saarni SI, Harkanen T, Sintonen H, Suvisaari J, Koskinen S, Aromaa A, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res. 2006;15(8):1403–14. doi:10.1007/s11136-006-0020-1.CrossRefPubMed

Vermani M, Marcus M, Katzman MA. Rates of detection of mood and anxiety disorders in primary care: a descriptive, cross-sectional study. Prim Care Companion CNS Disord. 2011;13(2); doi: 10.4088/PCC.10m01013.

Roberge P, Fournier L, Duhoux A, Nguyen CT, Smolders M. Mental health service use and treatment adequacy for anxiety disorders in Canada. Soc Psychiatry Psychiatr Epidemiol. 2011;46(4):321–30. doi:10.1007/s00127-010-0186-2.CrossRefPubMed

Sihvo S, Hämäläinen J, Kiviruusu O, Pirkola S, Isometsä E. Treatment of anxiety disorders in the Finnish general population. J Affect Disord. 2006;96(1-2):31–8. doi:10.1016/j.jad.2006.05.009.CrossRefPubMed

Weisberg RB, Dyck I, Culpepper L, Keller MB. Psychiatric treatment in primary care patients with anxiety disorders: a comparison of care received from primary care providers and psychiatrists. Am J Psychiatry. 2007;164(2):276–82.CrossRefPubMed

10.

Johnson EM, Coles ME. Failure and delay in treatment-seeking across anxiety disorders. Community Ment Health J. 2013;49(6):668–74. doi:10.1007/s10597-012-9543-9.CrossRefPubMed

11.

Wang PS, Berglund P, Olfson M, Pincus HA, Wells KB, Kessler RC. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):603–13. doi:10.1001/archpsyc.62.6.603.CrossRefPubMed

12.

Alonso J, Lepine JP, ESEMeD/MHEDEA 2000 Scientific Committee. Overview of key data from the European study of the epidemiology of mental disorders (ESEMeD). J Clin Psychiatry. 2007;68 Suppl 2:3–9.PubMed

13.

Mack S, Jacobi F, Gerschler A, Strehle J, Hofler M, Busch MA, et al. Self-reported utilization of mental health services in the adult German population--evidence for unmet needs? Results of the DEGS1-Mental Health Module (DEGS1-MH). Int J Methods Psychiatr Res. 2014;23(3):289–303. doi:10.1002/mpr.1438.CrossRefPubMed

14.

Hämäläinen J, Isometsä E, Sihvo S, Pirkola S, Kiviruusu O. Use of health services for major depressive and anxiety disorders in Finland. Depress Anxiety. 2008;25(1):27–37. doi:10.1002/da.20256.CrossRefPubMed

15.

Bunting B, Murphy S, O’Neill S, Ferry F. Prevalence and treatment of 12-month DSM-IV disorders in the Northern Ireland study of health and stress. Soc Psychiatry Psychiatr Epidemiol. 2013;48(1):81–93. doi:10.1007/s00127-012-0518-5.CrossRefPubMed

16.

Fernández A, Haro JM, Codony M, Vilagut G, Martínez-Alonso M, Autonell J, et al. Treatment adequacy of anxiety and depressive disorders: primary versus specialised care in Spain. J Affect Disord. 2006;96(1-2):9–20. doi:10.1016/j.jad.2006.05.005.CrossRefPubMed

17.

Weisberg RB, Beard C, Moitra E, Dyck I, Keller MB. Adequacy of treatment received by primary care patients with anxiety disorders. Depress Anxiety. 2014;31(5):443–50. doi:10.1002/da.22209.CrossRefPubMedPubMedCentral

18.

Cloos JM, Ferreira V. Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry. 2009;22(1):90–5. doi:10.1097/YCO.0b013e32831a473d.CrossRefPubMed

19.

Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014;77(2):295–301. doi:10.1111/j.1365-2125.2012.04418.x.CrossRefPubMedPubMedCentral

20.

Melo AP, Guimarães MD. Factors associated with psychiatric treatment dropout in a mental health reference center, Belo Horizonte. Rev Bras Psiquiatr. 2005;27(2):113–8. doi:10.1590/S1516-44462005000200008.CrossRefPubMed

21.

Olfson M, Mojtabai R, Sampson NA, Hwang I, Druss B, Wang PS, et al. Dropout from outpatient mental health care in the United States. Psychiatr Serv. 2009;60(7):898–907. doi:10.1176/appi.ps.60.7.898.CrossRefPubMedPubMedCentral

22.

Pinto-Meza A, Fernández A, Bruffaerts R, Alonso J, Kovess V, De Graaf R, et al. Dropping out of mental health treatment among patients with depression and anxiety by type of provider: results of the European Study of the Epidemiology of Mental Disorders. Soc Psychiatry Psychiatr Epidemiol. 2011;46(4):273–80. doi:10.1007/s00127-010-0195-1.CrossRefPubMed

23.

Wang J. Mental health treatment dropout and its correlates in a general population sample. Med Care. 2007;45(3):224–9. doi:10.1097/01.mlr.0000244506.86885.a5.CrossRefPubMed

24.

Killaspy H, Banerjee S, King M, Lloyd M. Prospective controlled study of psychiatric out-patient non-attendance. Characteristics and outcome. Br J Psychiatry. 2000;176(2):160–5. doi:10.1192/bjp.176.2.160.CrossRefPubMed

25.

Young AS, Grusky O, Jordan D, Belin TR. Routine outcome monitoring in a public mental health system: the impact of patients who leave care. Psychiatr Serv. 2000;51(1):85–91.CrossRefPubMed

26.

Suvisaari J, Aalto-Setala T, Tuulio-Henriksson A, Harkanen T, Saarni SI, Perala J, et al. Mental disorders in young adulthood. Psychol Med. 2009;39(2):287–99. doi:10.1017/S0033291708003632.CrossRefPubMed

27.

Kasteenpohja T, Marttunen M, Aalto-Setala T, Perala J, Saarni SI, Suvisaari J. Treatment received and treatment adequacy of depressive disorders among young adults in Finland. BMC Psychiatry. 2015;15(1):427. doi:10.1186/s12888-015-0427-8. -015-0427-8.CrossRef

28.

Aromaa A, Koskinen S, Kansanterveyslaitos. Health and functional capacity in Finland: baseline results of the Health 2000 health examination survey. Helsinki: National Public Health Institute; 2004.

29.

Heistaro S, Kansanterveyslaitos. Methodology report: Health 2000 Survey. Helsinki: National Public Health Institute; 2008.

30.

Pirkola SP, Isometsä E, Suvisaari J, Aro H, Joukamaa M, Poikolainen K, et al. DSM-IV mood-, anxiety- and alcohol use disorders and their comorbidity in the Finnish general population--results from the Health 2000 Study. Soc Psychiatry Psychiatr Epidemiol. 2005;40(1):1–10. doi:10.1007/s00127-005-0848-7.CrossRefPubMed

31.

First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders - Patient Edition (SCID I/P, 2/2001 Revision). New York State: Psychiatric Institute, Biometrics Research Department; 2001.

32.

Kessler RC. The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. J Clin Psychiatry. 2007;68 Suppl 2:10–9.PubMedPubMedCentral

33.

Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME. The diagnosis of and treatment recommendations for anxiety disorders. Dtsch Arztebl Int. 2014;111(27-28):473–80. doi:10.3238/arztebl.2014.0473.PubMedPubMedCentral

34.

Guidelines Advisory Committee. Clinical practice guidelines: Management of Anxiety Disorders. The Canadian Journal of Psychiatry. 2006; 51 Suppl 2:1-91.

35.

Choy Y, Fyer AJ, Lipsitz JD. Treatment of specific phobia in adults. Clin Psychol Rev. 2007;27(3):266–86. doi:10.1016/j.cpr.2006.10.002.CrossRefPubMed

36.

American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. In: APA Guidelines. American Psychiatric Association. 2009. http://psychiatryonline.org/guidelines.

37.

American Psychiatric Association. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. In: APA Guidelines. American Psychiatric Association. 2004. http://psychiatryonline.org/guidelines.

38.

American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. In: APA Guidelines. American Psychiatric Association. 2007. http://psychiatryonline.org/guidelines.

39.

National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management. In: NICE guidance. National Institute for Health and Care Excellence. 2011 http://www.nice.org.uk/guidance/cg113. Accessed Jan 2011.

40.

National Institute for Health and Care Excellence. Social anxiety disorder: recognition, assessment and treatment. In: NICE guidance. National Institute for Health and Care Excellence. 2013. http://www.nice.org.uk/guidance/cg159. Accessed May 2013.

41.

National Institute for Health and Care Excellence. Post-traumatic stress disorder: management. In: NICE guidance. National Institute for Health and Care Excellence. 2005. http://www.nice.org.uk/guidance/cg26. Accessed Mar 2005.

42.

National Institute for Health and Care Excellence. Obsessive-compulsive disorder and body dysmorphic disorder: treatment. In: NICE guidance. National Institute for Health and Care Excellence. 2005. http://www.nice.org.uk/guidance/cg31. Accessed Nov 2005.

43.

Fernández A, Haro JM, Martinez-Alonso M, Demyttenaere K, Brugha TS, Autonell J, et al. Treatment adequacy for anxiety and depressive disorders in six European countries. Br J Psychiatry. 2007;190:172–3. doi:10.1192/bjp.bp.106.023507.CrossRefPubMed

44.

Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):629–40. doi:10.1001/archpsyc.62.6.629.CrossRefPubMed

45.

Hämäläinen J, Isometsä E, Sihvo S, Kiviruusu O, Pirkola S, Lönnqvist J. Treatment of major depressive disorder in the Finnish general population. Depress Anxiety. 2009;26(11):1049–59. doi:10.1002/da.20524.CrossRefPubMed

46.

Dell’osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry. 2013;28(1):7–20. doi:10.1016/j.eurpsy.2011.11.003.CrossRefPubMed

47.

Santana L, Fontenelle LF. A review of studies concerning treatment adherence of patients with anxiety disorders. Patient Prefer Adherence. 2011;5:427–39. doi:10.2147/PPA.S23439.PubMedPubMedCentral

48.

Jenkins R, Lewis G, Bebbington P, Brugha T, Farrell M, Gill B, et al. The National Psychiatric Morbidity surveys of Great Britain--initial findings from the household survey. Psychol Med. 1997;27(4):775–89.CrossRefPubMed

Title: Treatment adequacy of anxiety disorders among young adults in Finland
Authors: Teija Kasteenpohja
Mauri Marttunen
Terhi Aalto-Setälä
Jonna Perälä
Samuli I. Saarni
Jaana Suvisaari
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Psychiatry / Issue 1/2016
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-016-0766-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Treatment adequacy of anxiety disorders among young adults in Finland

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication

No association between the rs10503253 polymorphism in the CSMD1 gene and schizophrenia in a Han Chinese population

Event-related potentials elicited by the Deutsch “high-low” word illusion in the patients with first-episode schizophrenia with auditory hallucinations

Type of childhood maltreatment and the risk of criminal recidivism in adult probationers: a cross-sectional study

Internet-based cognitive behavioural therapy for subthreshold depression: a systematic review and meta-analysis

Spatial suicide clusters in Australia between 2010 and 2012: a comparison of cluster and non-cluster among young people and adults